NO.1 Legendary Biology's 11 Early Cell Therapy Pipelines are Advancing

On January 15th Beijing time, Dr. Huang Ying, CEO of Legendary Biotech, gave a speech at the 43rd J.P. Morgan Healthcare Annual Meeting (JPM). Huang Ying introduced the progress of Legendary Biotech's core products, core technology platforms, and research pipelines. The company has currently established a CAR-T cell therapy product portfolio that includes 11 early-stage research and development pipelines, covering multiple fields such as hematological malignancies, solid tumors, and autoimmune diseases.

Comment: The report shows that Legendary Biology is advancing multiple research pipelines for autologous cell therapy/allogeneic cell therapy. These investigational therapies have a wide range of indications, not limited to multiple myeloma, but also include solid tumors such as autoimmune diseases, non Hodgkin lymphoma, small cell lung cancer, acute lymphoblastic leukemia, and hematological tumors.

NO.2 Sanofi/Regenerator IL-33 monoclonal antibody has been re approved for clinical use in China

The official website of the China National Medical Products Administration's Center for Drug Evaluation (CDE) announced that the Class 1 new drug itepekimab injection, applied by Sanofi, has been approved for clinical use and is intended for the treatment of patients with chronic sinusitis without nasal polyps (CRSsNP). Public information shows that this is a monoclonal antibody targeting IL-33, developed by Sanofi in collaboration with Regeneron. This product has previously obtained multiple implied licenses for clinical trials in China, with indications including the addition of maintenance therapy for the treatment of non cystic fibrosis bronchiectasis (NCFB) and moderate to severe chronic obstructive pulmonary disease (COPD) patients.

Comment: The therapeutic potential of targeting IL-33 antibodies has been preliminarily validated in studies targeting various diseases such as asthma, atopic dermatitis, and food allergies. Chronic sinusitis is a disease characterized by inflammation of the sinus mucosa with a course of more than 12 weeks, and there is currently a lack of specific targeted therapeutic drugs in clinical practice.

NO.3 Merck raises revenue expectations for its oncology business again in 2030

At the 43rd JP Morgan Healthcare Conference, Rob Davis, CEO of Merck, stated that the number of Phase III products under development by Merck in 2024 has almost doubled compared to 2021, and approximately $40 billion has been invested in BD transactions before and after. Given the potential of existing pipeline projects, Merck has once again raised its revenue forecast for its oncology business in 2030 from $20 billion to $25 billion.

Comment: In order to weaken its dependence on Keytruda, Merck has made a very comprehensive layout in the field of oncology, ADC、 There are various types of vaccines available, including multi antibodies, oncolytic viruses, and cancer vaccines.

NO.4 Lilly GLP-1 drug sales fall short of expectations

Lilly shared its basic sales performance for 2024 at this year's JPM conference, with an expected annual revenue of approximately $45 billion. Although this figure represents a 32% increase compared to 2023, it is $400 million lower than the lower limit of revenue expectations proposed in the third quarter financial report in October last year.

Comment: The growth of the intestinal insulinotropic drug market seems to have fallen short of expectations from Lilly or industry analysts. But there are many growth pathways in the GLP-1 market, such as last month's approval of liraglutide for the treatment of sleep apnea.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Based on this operation, the risk is borne by oneself.